Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer <p>Prostate Cancer and Prostatic Diseases, Published online: 10 December 2025; <a href="https://www.nature.com/articles/s41391-025-01064-6">doi:10.1038/s41391-025-01064-6</a></p>Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer Prostate Cancer Journal December 11, 2025 Original source
Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy? <p>Prostate Cancer and Prostatic Diseases, Published online: 11 December 2025; <a href="https://www.nature.com/articles/s41391-025-01056-6">doi:10.1038/s41391-025-01056-6</a></p>Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy? Prostate Cancer Journal December 11, 2025 Original source
Deep Learning Discriminates Thymic Epithelial Tumors Histological Subtypes Using Digital Pathology Thymic epithelial tumors (TETs) are rare malignancies that pose significant diagnostic challenges due to their heterogeneous histological patterns and substantial interobserver variability in classification.Despite standardized World Health Organization (WHO) classification criteria, diagnostic concordance remains suboptimal, particularly in non-expert settings, where second-opinion reviews lead to diagnostic reclassification in up to 57% of cases.Deep learning may offer a tool to reduce diagnostic… Annals of Oncology December 11, 2025 Original source
20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment Twenty years after its initial approval, trastuzumab remains a cornerstone in the treatment of patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC). Long-term follow-up from pivotal adjuvant trials has consistently demonstrated significant and durable improvements in survival outcomes across various risk groups and chemotherapy backbones. In parallel, trastuzumab-induced cardiotoxicity (TIC) remains overall infrequent, particularly… Annals of Oncology December 10, 2025 Original source
The PARP inhibitor/Immunotherapy Paradox in Advanced Ovarian Cancer: Positive Endpoints, Perplexing Interpretations Unlocking the immune system with antibodies targeting PD-1/L1 and CTLA-4 has opened broad new therapeutic areas in oncology, including the treatment of gynaecological cancers involving the endometrium and cervix1. Not unreasonably, researchers hoped that the benefits of immune checkpoint inhibitors would extend to ovarian cancer, a heterogenous group of tumours in which previous studies showed that the presence of infiltrating… Annals of Oncology December 10, 2025 Original source
Positivity Helps Patient Keep Up the Fight <p>On July 20, 2009, Michele Milso was leaving the gym when she received a call from her radiologist. That call changed her life.   “He told me I have breast cancer,” says Milso, who lives in Bridgewater, Massachusetts. “It was the last thing I thought I’d hear.”   To maintain a healthy lifestyle, Milso ate well, exercised ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/12/positivity-helps-patient-keep-up-the-fight/" title="Positivity… Dana-Farber Cancer Institute December 10, 2025 Original source
Being in the zone <p>Nature Reviews Cancer, Published online: 09 December 2025; <a href="https://www.nature.com/articles/s41568-025-00899-4">doi:10.1038/s41568-025-00899-4</a></p>A study published in Science shows that liver zonation shapes hepatocellular carcinoma (HCC) development. In mice, HCC predominantly originates from zone 3 hepatocytes, where GSTM2 and GSTM3 drive initiation by inhibiting ferroptosis, revealing metabolic vulnerabilities in liver cancer. Nature Reviews Cancer December 9, 2025 Original source
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer Despite treatment advances in newly diagnosed advanced stage ovarian cancer (aOC), improved outcomes are needed. Annals of Oncology December 9, 2025 Original source
<i>N</i><sup>6</sup>-Methyladenosine: an RNA modification as a central regulator of cancer <p>Nature Reviews Cancer, Published online: 08 December 2025; <a href="https://www.nature.com/articles/s41568-025-00889-6">doi:10.1038/s41568-025-00889-6</a></p>In this Review Luo, Kharas and Jaffrey outline how N6-methyladenosine (m6A) RNA modification affects RNA stability, translation, splicing and immune responses to influence cancer biology. They discuss emerging evidence on how m6A may influence cancer metabolic reprogramming and outline the challenges and opportunities of targeting m6A writers, erasers and readers for… Nature Reviews Cancer December 8, 2025 Original source
Targeting phagocytosis checkpoints for cancer immunotherapy <p>Nature Reviews Cancer, Published online: 08 December 2025; <a href="https://www.nature.com/articles/s41568-025-00893-w">doi:10.1038/s41568-025-00893-w</a></p>Macrophages can eliminate cancer cells through phagocytosis, which is tightly regulated through inhibition and activation of various phagocytic receptors. In this Review, Veillette and colleagues outline how targeting these phagocytic checkpoints could be harnessed therapeutically, address therapeutic efficacy concerns, and propose strategies to enhance therapeutic outcomes in future clinical applications. Nature Reviews Cancer December 8, 2025 Original source
A new framework for engaging patients and the public in basic cancer research <p>Nature Reviews Cancer, Published online: 08 December 2025; <a href="https://www.nature.com/articles/s41568-025-00898-5">doi:10.1038/s41568-025-00898-5</a></p>Patient and public involvement and engagement (PPIE), although well established in clinical settings, remains less well defined in laboratory-based settings, where infrastructure to support meaningful collaboration is limited. In this Comment, the authors propose a novel framework for embedding PPIE ambassadors into basic cancer research pipelines, outlining strategies to address power… Nature Reviews Cancer December 8, 2025 Original source
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase 2 study from the Italian Sarcoma Group Advanced/metastatic soft tissue sarcomas (STS) remain an unmet clinical need. We previously reported the feasibility and preliminary activity of trabectedin-olaparib combination in patients with advanced STS progressing after anthracycline-based regimens. Annals of Oncology December 8, 2025 Original source
Deep learning algorithm assisting diagnosis of prostate cancer extracapsular extension based on [<sup>18</sup>F]PSMA-1007 PET/CT and multiparametric MRI: A multicenter study <p>Prostate Cancer and Prostatic Diseases, Published online: 08 December 2025; <a href="https://www.nature.com/articles/s41391-025-01063-7">doi:10.1038/s41391-025-01063-7</a></p>Deep learning algorithm assisting diagnosis of prostate cancer extracapsular extension based on [<sup>18</sup>F]PSMA-1007 PET/CT and multiparametric MRI: A multicenter study Prostate Cancer Journal December 8, 2025 Original source
Prognostic Factors Affecting Iodine-131 Treatment Efficacy in Patients With Differentiated Thyroid Carcinoma: A Risk-Stratified Analysis . <br /> Nutrition and Cancer Journal December 8, 2025 Original source
Adherence to Oral Nutritional Support and Its Effect on Nutritional Status in Pediatric Oncology Patients . <br /> Nutrition and Cancer Journal December 8, 2025 Original source
A rapid urinary test for combining PSA and zinc to enhance prostate cancer diagnosis: results from a prospective study <p>Prostate Cancer and Prostatic Diseases, Published online: 08 December 2025; <a href="https://www.nature.com/articles/s41391-025-01030-2">doi:10.1038/s41391-025-01030-2</a></p>A rapid urinary test for combining PSA and zinc to enhance prostate cancer diagnosis: results from a prospective study Prostate Cancer Journal December 8, 2025 Original source
Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures <p>Prostate Cancer and Prostatic Diseases, Published online: 05 December 2025; <a href="https://www.nature.com/articles/s41391-025-01061-9">doi:10.1038/s41391-025-01061-9</a></p>Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures Prostate Cancer Journal December 5, 2025 Original source
Multiparametric prostate MRI improves the diagnosis of a clinically significant prostate cancer in PSA screening; but what is the benefit of additional risk calculators? <p>Prostate Cancer and Prostatic Diseases, Published online: 04 December 2025; <a href="https://www.nature.com/articles/s41391-025-01058-4">doi:10.1038/s41391-025-01058-4</a></p>Multiparametric prostate MRI improves the diagnosis of a clinically significant prostate cancer in PSA screening; but what is the benefit of additional risk calculators? Prostate Cancer Journal December 4, 2025 Original source
The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors <p>Nature Reviews Cancer, Published online: 03 December 2025; <a href="https://www.nature.com/articles/s41568-025-00890-z">doi:10.1038/s41568-025-00890-z</a></p>Concomitant medications are emerging as a modifiable prognostic factor for immune checkpoint inhibitor treatment outcomes. This Review by Stone et al. highlights the potential immunomodulatory interactions of commonly prescribed medications and supplements, and proposes strategies to make better use of this information to guide clinical care. Nature Reviews Cancer December 3, 2025 Original source